<DOC>
	<DOCNO>NCT00603109</DOCNO>
	<brief_summary>The purpose study evaluate effect rimonabant , cannabinoid receptor-1 block drug , appetite , body weight , body fat growth hormone level subject Prader-Willi Syndrome ( PWS ) . This double blind placebo control clinical trial involve total 18 young adult age 18 35 year PWS . Patients divide two group control intervention , treat either placebo ( inactive drug ) , rimonabant 20 mg day total duration 6 month . Body weight , fat distribution , objective subjective assessment hunger , fast blood sample measurement ghrelin leptin ( two hormone regulate appetite ) , serum lipid , IGF-1 ( growth hormone relate protein ) , insulin glucose concentration measure upon enrollment , 3 month , end study . The proportion body fat muscle determine use radiological technique , whole body dual-energy x-ray absorptiometry ( DEXA ) scan , also measurement skin fold thickness , waist hip circumference enrollment prior intervention , end study .</brief_summary>
	<brief_title>Effect Rimonabant Weight Gain Body Composition Adults With Prader Willi Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Prader-Willi Syndrome</mesh_term>
	<mesh_term>Rimonabant</mesh_term>
	<criteria>1 . Subjects select Prader Willi Syndrome previously confirm standard genetic testing ( DNA methylation test ) meet clinical diagnostic criterion follow : presence least four six principal characteristic PWS syndrome include 1 ) infantile hypotonia , 2 ) abnormal pubertal development , 3 ) obesity early infancy , 4 ) dysfunctional central nervous system performance , 5 ) dysmorphic facial feature , 6 ) short stature . In addition , must one follow characteristic commonly associate PWS : 1 ) small hand foot , 2 ) skin problem , 3 ) behavioral problem relate food , 4 ) decrease pain sensitivity . 2 . Subjects must 18 35 year age fairly cooperative study protocol . 3 . Subjects must BMI least 30 . 1 . Presence pulmonary disease . 2 . Presence abnormal endocrine finding , include abnormal thyroid function . 3 . Presence significant behavioral problem psychiatric illness include anxiety disorder depression , interfere follow protocol . Any degree depression moderate severe anxiety exclusion criterion study . 4 . Subjects Prader Willi Syndrome medication include growth hormone therapy , anti epileptic medication , antipsychotic medication . 5 . The presence moderate severe renal liver disease . Mild elevation liver enzymes exclusive . 6 . Subjects research weight loss medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Body weight , fat mass , growth hormone , ghrelin</keyword>
</DOC>